Drugs / 1018 ISS immunostimulatory oligonucleotide
1018 ISS immunostimulatory oligonucleotide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00403052 | Nov 2006 → Dec 2007 | colorectal neoplasm | Dynavax Technologies Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1018 ISS immunostimulatory oligonucleotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00403052 ↗ |
| Modality | Oligonucleotide (other) | “1018 ISS immunostimulatory oligonucleotide” NCT00403052 ↗ |
| Route | Subcutaneous | “6 weekly subcutaneous (under the skin) injections” NCT00403052 ↗ |